Spain Atopic Dermatitis Drugs Market Size & Outlook
Spain atopic dermatitis drugs market, 2018-2030 (US$M)
Related Markets
Spain atopic dermatitis drugs market highlights
- The Spain atopic dermatitis drugs market generated a revenue of USD 386.1 million in 2024 and is expected to reach USD 679.3 million by 2030.
- The Spain market is expected to grow at a CAGR of 9.7% from 2025 to 2030.
- In terms of segment, biologics was the largest revenue generating drug class in 2024.
- PDE4 Inhibitors is the most lucrative drug class segment registering the fastest growth during the forecast period.
Atopic dermatitis drugs market data book summary
| Market revenue in 2024 | USD 386.1 million |
| Market revenue in 2030 | USD 679.3 million |
| Growth rate | 9.7% (CAGR from 2025 to 2030) |
| Largest segment | Biologics |
| Fastest growing segment | PDE4 Inhibitors |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Corticosteroids, Calcineurin Inhibitors, PDE4 Inhibitors, Biologics |
| Key market players worldwide | Pfizer Inc, Sanofi SA, AbbVie Inc, Galderma Group AG Registered Shares, Eli Lilly and Co, Regeneron Pharmaceuticals Inc, Otsuka Holdings Co Ltd, Novartis AG ADR, Incyte Corp, LEO Pharma |
Other key industry trends
- In terms of revenue, Spain accounted for 2.2% of the global atopic dermatitis drugs market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany atopic dermatitis drugs market is projected to lead the regional market in terms of revenue in 2030.
- France is the fastest growing regional market in Europe and is projected to reach USD 1,226.3 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Atopic Dermatitis Drugs Market Scope
Atopic Dermatitis Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Spain atopic dermatitis drugs market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to atopic dermatitis drugs market will help companies and investors design strategic landscapes.
Biologics was the largest segment with a revenue share of 45.27% in 2024. Horizon Databook has segmented the Spain atopic dermatitis drugs market based on corticosteroids, calcineurin inhibitors, pde4 inhibitors, biologics covering the revenue growth of each sub-segment from 2018 to 2030.
The most commonly used treatments for atopic dermatitis in this country are corticosteroids (~90%), cyclosporine, azathioprine, and methotrexate. However, use of novel biologics is as low as 5.8%. As per NCBI in 2019, the constant use of immunosuppressants in atopic dermatitis patients is increasing their susceptibility to other conditions, which is expected to restrain the market.
Spanish pharmaceutical company Almirall S.A.is evaluating the use of Lebrikizumab for treating severe and moderate atopic dermatitis. Phase 3 of the study started in October 2019. The company has exclusive development rights for the product.
Spain was affected severely by the COVID-19 pandemic, which led to lifestyle changes such as frequent hand-washing and increased use of alcohol-based sanitizers, further increasing the incidence of hand atopic dermatitis. This is expected to propel the country’s market.
Reasons to subscribe to Spain atopic dermatitis drugs market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Spain atopic dermatitis drugs market databook
-
Our clientele includes a mix of atopic dermatitis drugs market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Spain atopic dermatitis drugs market , including forecasts for subscribers. This country databook contains high-level insights into Spain atopic dermatitis drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Spain atopic dermatitis drugs market size, by drug class, 2018-2030 (US$M)
Spain Atopic Dermatitis Drugs Market Outlook Share, 2024 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
